LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

Home・Akciju saraksts・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

66.17 1.16

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

64.29

Max

66.21

Galvenie mērījumi
By Trading Economics
Ienākumi	-5.6M -82M
Pārdošana	-8.7M 2.8M
EPS	-0.94
Peļņas marža	-2,973.046
Darbinieki	225
EBITDA	5.2M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+14.19% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	541M 4.8B
Iepriekšējā atvēršanas cena	65.01
Iepriekšējā slēgšanas cena	66.17

Ziņu noskaņojums

By Acuity

50%

167 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

28.34 / 33.56 Atbalsts un pretestība

Kymera Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. dec. 23:21 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025. g. 3. dec. 23:14 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025. g. 3. dec. 22:01 UTC

Galvenie tirgus virzītāji

Costco Wholesale Reports Higher Monthly Sales

2025. g. 3. dec. 21:38 UTC

Peļņas

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025. g. 3. dec. 23:59 UTC

Tirgus saruna

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025. g. 3. dec. 23:13 UTC

Tirgus saruna

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025. g. 3. dec. 23:10 UTC

Peļņas

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025. g. 3. dec. 23:08 UTC

Tirgus saruna

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025. g. 3. dec. 23:06 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025. g. 3. dec. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy PC Financial From Loblaw for About $573.5M

2025. g. 3. dec. 22:45 UTC

Tirgus saruna

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025. g. 3. dec. 22:20 UTC

Peļņas

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025. g. 3. dec. 22:19 UTC

Peļņas

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025. g. 3. dec. 22:17 UTC

Peļņas

Salesforce Working to Add Voice to Agentforce, CEO Says

2025. g. 3. dec. 22:16 UTC

Peļņas

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025. g. 3. dec. 22:15 UTC

Peļņas

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025. g. 3. dec. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025. g. 3. dec. 22:09 UTC

Iegādes, apvienošanās, pārņemšana

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025. g. 3. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 3. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. dec. 21:49 UTC

Peļņas

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:23 UTC

Peļņas

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025. g. 3. dec. 21:19 UTC

Peļņas

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:06 UTC

Peļņas

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:04 UTC

Peļņas

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025. g. 3. dec. 21:04 UTC

Peļņas

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025. g. 3. dec. 21:03 UTC

Peļņas

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Salīdzinājums

Cenas izmaiņa

Kymera Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

14.19% augšup

Prognoze 12 mēnešiem

Vidējais 76.35 USD 14.19%

Augstākais 98 USD

Zemākais 53 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Kymera Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

21 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 21 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Kymera Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

28.34 / 33.56Atbalsts un pretestība

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

167 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.